Incorporation by coordination and release of the iron chelator drug deferiprone from zinc-based metal-organic frameworks Article (Published Version) http://sro.sussex.ac.uk Burrows, Andrew D, Jurcic, Monika, Keenan, Luke L, Lane, Rebecca A, Mahon, Mary F, Warren, Mark R, Nowell, Harriot, Paradowski, Michael and Spencer, John (2013) Incorporation by coordination and release of the iron chelator drug deferiprone from zinc-based metal-organic frameworks. Chemical Communications, 49. pp. 11260-11262. ISSN 1359-7345 This version is available from Sussex Research Online: http://sro.sussex.ac.uk/46792/ This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the URL above for details on accessing the published version.
Copyright and reuse:Sussex Research Online is a digital repository of the research output of the University.Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. Metal-organic frameworks (MOFs) are attracting considerable attention due to their potential for permanent porosity, and the consequent applications of this in areas as diverse as hydrogen storage, separations and heterogeneous catalysis.1 Since the first report, in 2006, that bioactive molecules could be encapsulated within the pores of MOFs and released slowly, 2 there has been an increased focus on using MOFs to control drug delivery.3 As an alternative to including bioactive molecules as guests within pores of a pre-formed MOF, it is also possible to use this kind of molecule as a component of the framework itself. 4 An u m b e ro fe x a m p l e s have been reported, including those in which nicotinate, 5 glutarate 6 and theophylline 7 have been incorporated as linkers. Many MOFs can be prepared with coordinatively unsaturated metal centres, and small bioactive molecules such as NO have been incorporated into such systems by coordination to these metal sites. 8 In this communication, we report our initial studies on the inclusion into MOFs of the iron chelator drug deferiprone (Hdfp), which is used as an oral treatment for haemosiderosis (iron overload) that can occur as a consequence of regular blood transfusions required in the treatment of conditions such as thalassaemia major and haemochromatosis.9 Deferiprone has high sel...